Clinical Updates
Latest news
1078 articles · 20 / page
Dissecting the Care Bundle: Mediation Analysis of Key Components Driving Improved Outcomes in INTERACT3 for Acute Intracerebral Hemorrhage
Mediation analysis of INTERACT3 reveals that systolic blood pressure and blood glucose control are primary drivers of functional recovery benefits in acute intracerebral hemorrhage care bundles.
Immunogenicity and Safety of the VLA15 Lyme Borreliosis Vaccine Across Age Groups: A Phase 2 Randomised Controlled Trial and Integrative Review
This review synthesizes data on the VLA15 Lyme borreliosis vaccine candidate, demonstrating its safety and robust immunogenicity in adults, adolescents, and children, supporting multi-dose schedules and highlighting enhanced antibody respon
Adjunctive Corticosteroids in Severe Pneumocystis jirovecii Pneumonia Among HIV-negative Patients: Insights from a Multicentre Randomised Trial
A multicentre randomized trial evaluated adjunctive corticosteroids in HIV-negative severe Pneumocystis jirovecii pneumonia, showing a non-significant reduction in 28-day mortality and no safety concerns, and calls for further targeted rese
Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial
The endTB-Q trial assessed the efficacy and safety of a shortened BDLC regimen versus WHO standard care in rifampicin-resistant and fluoroquinolone-resistant tuberculosis, finding BDLC non-inferior in mITT but overall not non-inferior, high
Theta Burst Stimulation of the Temporo-Parietal Cortex for Persistent Auditory Hallucinations in Schizophrenia: A Comprehensive Review of a Phase 3 Randomised Multicentre Trial and Contextual Evidence
This review synthesizes evidence on bilateral continuous theta burst stimulation (cTBS) of the temporo-parietal cortex for persistent auditory verbal hallucinations (AVH) in schizophrenia, focusing on a landmark German phase 3 trial demonst
Oral Decitabine and Cedazuridine Maintenance Post-HSCT: Promising Strategy in High-Risk AML and MDS
A phase 2 trial demonstrates that oral hypomethylating agent ASTX727, with optional donor lymphocyte infusion, shows encouraging disease-free survival and manageable safety after stem-cell transplantation in very high-risk acute myeloid leu
Oral Decitabine and Cedazuridine as Maintenance Therapy Post-HSCT in Very High-Risk AML and MDS: Insights from the GFM-DACORAL-DLI Phase 2 Trial
A phase 2 trial demonstrates that oral decitabine and cedazuridine maintenance following hematopoietic stem-cell transplantation may improve disease-free survival in very high-risk AML and MDS patients with manageable safety.
Enhancing Malaria Control in West Africa: Combining Non-Pyrethroid Indoor Residual Spraying or Intensive Behaviour Change Communication with Long-Lasting Insecticidal Nets
This trial shows that adding non-pyrethroid indoor residual spraying (IRS) or intensive behaviour change communication (BCC) to long-lasting insecticidal nets (LLINs) reduces malaria incidence by over 20% in West African rural communities,
Advancing Treatment in Oligometastatic Castration-Resistant Prostate Cancer: The GROUQ-PCS 9 Trial on SBRT Plus Standard Systemic Therapy
The GROUQ-PCS 9 trial demonstrates that adding stereotactic body radiotherapy to standard androgen deprivation therapy and enzalutamide significantly prolongs radiographic progression-free survival in oligometastatic castration-resistant pr
Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial
The PECATI phase 2 trial demonstrates that lenvatinib combined with pembrolizumab offers encouraging antitumour activity and a manageable safety profile in platinum-refractory metastatic B3 thymoma and thymic carcinoma, a population with li
De-escalated Adjuvant Radiotherapy in HPV-Associated Oropharyngeal Cancer: Balancing Efficacy with Reduced Toxicity
This phase 3 trial shows that de-escalated adjuvant radiotherapy reduces chronic grade 3+ toxicities compared to standard chemoradiotherapy in HPV-associated oropharyngeal cancer, potentially improving patient quality of life without compro
Enhanced Progression-Free Survival with Ibrutinib Plus Rituximab in CXCR4-Mutated Waldenström Macroglobulinemia: Insights from a Pooled Analysis
A pooled analysis of prospective studies shows ibrutinib plus rituximab improves progression-free survival in Waldenström macroglobulinemia patients with CXCR4 mutations compared to ibrutinib alone, supporting routine CXCR4 testing and comb
Maintenance Romidepsin Therapy Post-AHCT in Peripheral T-Cell Lymphoma: Feasibility and Outcomes from a Multicenter Phase 2 Study
Maintenance therapy with romidepsin following autologous hematopoietic stem-cell transplantation (AHCT) in peripheral T-cell lymphoma (PTCL) demonstrated feasibility and an estimated 2-year progression-free survival (PFS) of 62%, though the
Expanding the Role of Stereotactic Radiosurgery in Small Cell Lung Cancer with Brain Metastases: Insights from a Prospective Multicenter Phase II Trial
A prospective phase II trial shows stereotactic radiosurgery offers a low neurologic death rate in SCLC patients with 1-10 brain metastases, challenging the traditional favoring of whole-brain radiation therapy.
Innovative Combination of Cryoablation and Intratumoral Immunotherapy Extends Survival in Advanced Metastatic Cancer
A phase II trial demonstrates that multiplex intratumoral immunotherapy combining cryoablation with low-dose immune checkpoint inhibitors significantly prolongs median overall survival to 20.9 months in treatment-refractory metastatic solid
PegIFN Alpha-2a Therapy Reduces Relapse Risk after NUC Discontinuation in HBeAg-Negative Chronic Hepatitis B: Insights from a Randomized Controlled Trial
Switching from nucleo(s)tide analogues to pegylated interferon alpha-2a significantly lowers virological relapse and boosts HBsAg clearance in HBeAg-negative chronic hepatitis B patients after treatment cessation.
Rapirosiran: A Promising RNA Interference Therapy Targeting HSD17B13 for Metabolic Dysfunction-Associated Steatohepatitis
This phase I randomized study shows rapirosiran, an RNAi therapeutic targeting HSD17B13, is safe and effectively reduces liver HSD17B13 mRNA in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Sequential Pegylated Interferon after Bepirovirsen Lowers Relapse Risk in Chronic Hepatitis B: Insights from the B-Together Trial
The B-Together phase IIb study demonstrates that sequential therapy with bepirovirsen followed by pegylated interferon-α-2a reduces post-treatment relapse in chronic hepatitis B patients on stable nucleos(t)ide analogue therapy, with enhanc
Predictive Power of Circulating Tumor DNA in Managing Resected Extrahepatic Cholangiocarcinoma
Monitoring circulating tumor DNA (ctDNA) post-surgery accurately predicts recurrence risk in extrahepatic cholangiocarcinoma, guiding personalized adjuvant chemotherapy decisions and improving patient outcomes.
Enhancing Fibrosis Scoring in MASH: The Role of AI-Enhanced Digital Pathology
AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.
Browse by specialty
Open language-specific specialty feeds and department pages.